The stock of Enfusion Inc (ENFN) has gone up by 6.64% for the week, with a 1.69% rise in the past month and a 19.99% rise in the past quarter. The volatility ratio for the week is 3.63%, and the volatility levels for the past 30 days are 4.23% for ENFN. The simple moving average for the last 20 days is 2.85% for ENFN stock, with a simple moving average of 16.91% for the last 200 days.
Is It Worth Investing in Enfusion Inc (NYSE: ENFN) Right Now?
The price-to-earnings ratio for Enfusion Inc (NYSE: ENFN) is above average at 409.88x. The 36-month beta value for ENFN is also noteworthy at 0.95. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENFN is 49.29M, and at present, short sellers hold a 1.13% of that float. The average trading volume of ENFN on January 13, 2025 was 448.11K shares.
ENFN) stock’s latest price update
Enfusion Inc (NYSE: ENFN)’s stock price has increased by 8.04 compared to its previous closing price of 9.94. However, the company has seen a 6.64% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-01-13 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.
Analysts’ Opinion of ENFN
Many brokerage firms have already submitted their reports for ENFN stocks, with Morgan Stanley repeating the rating for ENFN by listing it as a “Overweight.” The predicted price for ENFN in the upcoming period, according to Morgan Stanley is $11 based on the research report published on May 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ENFN reach a price target of $8, previously predicting the price at $9. The rating they have provided for ENFN stocks is “Sell” according to the report published on February 28th, 2024.
JP Morgan gave a rating of “Underweight” to ENFN, setting the target price at $9 in the report published on January 30th of the previous year.
ENFN Trading at 6.99% from the 50-Day Moving Average
After a stumble in the market that brought ENFN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.59% of loss for the given period.
Volatility was left at 4.23%, however, over the last 30 days, the volatility rate increased by 3.63%, as shares surge +1.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.76% upper at present.
During the last 5 trading sessions, ENFN rose by +7.25%, which changed the moving average for the period of 200-days by +18.68% in comparison to the 20-day moving average, which settled at $10.44. In addition, Enfusion Inc saw 4.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENFN starting from Movchan Oleg, who sale 2,771 shares at the price of $10.13 back on Jan 07 ’25. After this action, Movchan Oleg now owns 526,702 shares of Enfusion Inc, valued at $28,070 using the latest closing price.
Herring Bradley, the Chief Financial Officer of Enfusion Inc, sale 4,134 shares at $10.13 during a trade that took place back on Jan 07 ’25, which means that Herring Bradley is holding 266,369 shares at $41,877 based on the most recent closing price.
Stock Fundamentals for ENFN
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.67 for the gross margin
The net margin for Enfusion Inc stands at 0.02. The total capital return value is set at 0.06. Equity return is now at value 5.54, with 2.82 for asset returns.
Based on Enfusion Inc (ENFN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 5.13. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 22.13.
Currently, EBITDA for the company is 21.93 million with net debt to EBITDA at -1.54. When we switch over and look at the enterprise to sales, we see a ratio of 5.08. The receivables turnover for the company is 6.07for trailing twelve months and the total asset turnover is 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In summary, Enfusion Inc (ENFN) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
